Movantik (naloxegol) — United Healthcare
opioid-induced constipation in patients being treated for chronic, non-cancer pain
Initial criteria
- Diagnosis of opioid-induced constipation in patients being treated for chronic, non-cancer pain OR
- Diagnosis of opioid-induced constipation in patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation
Reauthorization criteria
- Documentation of positive clinical response to therapy
Approval duration
12 months